The successful completion of a Phase 3 study is a significant milestone for any biotech company, often leading to increased investor confidence and a rise in share price. As Neurocrine Biosciences' CAHtalyst Pediatric Study met its primary endpoint, this is likely to have a positive impact on the company's stock in the short term.